285 related articles for article (PubMed ID: 28240217)
1. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
3. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
4. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent.
Frinking PJ; Tardy I; Théraulaz M; Arditi M; Powers J; Pochon S; Tranquart F
Ultrasound Med Biol; 2012 Aug; 38(8):1460-9. PubMed ID: 22579540
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer.
Turco S; El Kaffas A; Zhou J; Lutz AM; Wijkstra H; Willmann JK; Mischi M
Mol Imaging Biol; 2019 Aug; 21(4):633-643. PubMed ID: 30225758
[TBL] [Abstract][Full Text] [Related]
7. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
[TBL] [Abstract][Full Text] [Related]
9. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
11. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
[TBL] [Abstract][Full Text] [Related]
12. Ultra-Low-Dose Ultrasound Molecular Imaging for the Detection of Angiogenesis in a Mouse Murine Tumor Model: How Little Can We See?
Wang S; Herbst EB; Mauldin FW; Diakova GB; Klibanov AL; Hossack JA
Invest Radiol; 2016 Dec; 51(12):758-766. PubMed ID: 27654582
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2-targeted molecular imaging in the mouse embryo: an alternative to the tumor model.
Denbeigh JM; Nixon BA; Hudson JM; Puri MC; Foster FS
Ultrasound Med Biol; 2014 Feb; 40(2):389-99. PubMed ID: 24342913
[TBL] [Abstract][Full Text] [Related]
14. Influence of repetitive contrast agent injections on functional and molecular ultrasound measurements.
Rix A; Palmowski M; Gremse F; Palmowski K; Lederle W; Kiessling F; Bzyl J
Ultrasound Med Biol; 2014 Oct; 40(10):2468-75. PubMed ID: 25023096
[TBL] [Abstract][Full Text] [Related]
15. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.
Wang J; Qin B; Chen X; Wagner WR; Villanueva FS
Mol Pharm; 2017 Mar; 14(3):781-790. PubMed ID: 28165246
[TBL] [Abstract][Full Text] [Related]
17. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
[TBL] [Abstract][Full Text] [Related]
18. Dual-Targeted Microbubbles Specific to Integrin αVβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.
Yuan HX; Wang WP; Wen JX; Lin LW; Exner AA; Guan PS; Chen XJ
Ultrasound Med Biol; 2018 Jul; 44(7):1460-1467. PubMed ID: 29706409
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.
Willmann JK; Bonomo L; Testa AC; Rinaldi P; Rindi G; Valluru KS; Petrone G; Martini M; Lutz AM; Gambhir SS
J Clin Oncol; 2017 Jul; 35(19):2133-2140. PubMed ID: 28291391
[TBL] [Abstract][Full Text] [Related]
20. In vivo quantification of ultrasound targeted microbubbles to enhance cancer assessment.
Sciallero C; Daglio E; Trucco A
Contrast Media Mol Imaging; 2016 Jul; 11(4):313-8. PubMed ID: 27157493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
